MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Bristol-Myers Squibb Co.

Abrir

SetorSaúde

47.7 -1.45

Visão Geral

Variação de preço das ações

24h

Atual

Mín

46.95

Máximo

48.84

Indicadores-chave

By Trading Economics

Rendimento

-1.1B

76M

Vendas

442M

12B

P/E

Médio do Setor

14.05

57.333

EPS

1.67

Rendimento de Dividendos

5.04

Margem de lucro

0.616

Funcionários

34,100

EBITDA

-1.9B

2.6B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+18.22% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

5.04%

2.63%

Próxima data de dividendos

1 de mai. de 2025

Próxima data de ex-dividendo

4 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-21B

100B

Abertura anterior

49.15

Fecho anterior

47.7

Pontuação Técnica

By Trading Central

Confiança

Neutral Evidence

Bristol-Myers Squibb Co. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de abr. de 2025, 11:32 UTC

Ganhos

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

11 de mar. de 2025, 10:13 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11 de mar. de 2025, 10:13 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

24 de abr. de 2025, 21:24 UTC

Principais Notícias
Ganhos

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 de abr. de 2025, 14:15 UTC

Principais Notícias
Ganhos

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 de abr. de 2025, 12:37 UTC

Conversa de Mercado
Ganhos

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

24 de abr. de 2025, 11:17 UTC

Ganhos

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

24 de abr. de 2025, 11:13 UTC

Principais Notícias
Ganhos

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 20% to $5.64B >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Adj EPS $1.80 >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb Raises 2025 View To Rev $45.8B-$46.8B Vs Prior View $45.5B >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Gross Margin 72.9% >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb Raises 2025 View To Adj EPS $6.70-Adj EPS $7.00 Vs Prior View $6.55-$6.85 >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Rev $11.2B >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q EPS $1.20 >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol-Myers Squibb 1Q Adj EPS $1.80 >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol-Myers Squibb 1Q Rev $11.2B >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol-Myers Squibb 1Q Net $2.46B >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol-Myers Squibb Sees FY Adj EPS $6.70-Adj EPS $7.00 >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol-Myers Squibb 1Q EPS $1.20 >BMY

14 de mar. de 2025, 09:30 UTC

Principais Notícias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Comparação entre Pares

Variação de preço

Bristol-Myers Squibb Co. Previsão

Preço-alvo

By TipRanks

18.22% parte superior

Previsão para 12 meses

Média 57.56 USD  18.22%

Máximo 70 USD

Mínimo 36 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Bristol-Myers Squibb Co. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

19 ratings

5

Comprar

13

Manter

1

Vender

Pontuação Técnica

By Trading Central

47.54 / 48.82Suporte e Resistência

Curto Prazo

Neutral Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Strong Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.